Rapamycin

Rapamycin (sirolimus) is an FDA-approved immunosuppressant used at therapeutic doses to prevent organ transplant rejection and treat certain medical conditions. At much lower doses taken intermittently, rapamycin has become one of the most discussed agents in longevity medicine due to its inhibition of mechanistic target of rapamycin (mTOR) -- a key intracellular signaling hub that regulates cell growth, protein synthesis, autophagy, and metabolic sensing. Rapamycin is the only agent to date demonstrated to extend lifespan in multiple independent animal models, including mice, and this has driven significant interest in its application for human longevity.

The mTOR pathway integrates nutrient availability and growth signals to govern whether cells prioritize growth and protein synthesis versus cellular maintenance and autophagy -- the process by which cells clear damaged components. Chronic mTOR overactivation, which increases with age and caloric excess, is thought to impair cellular maintenance programs. Low-dose intermittent rapamycin is hypothesized to partially inhibit mTOR in a way that may shift the balance toward cellular housekeeping without the degree of immunosuppression seen at transplant doses. This use pattern is being studied, but rigorous long-term human trials are limited.

Off-label longevity protocols typically involve weekly or every-other-week oral dosing at low doses, which differ substantially from the daily immunosuppressive doses used in transplant medicine. The intermittent schedule is thought to reduce the risk of cumulative immunosuppression while preserving proposed benefits on cellular quality control pathways. Your provider will discuss appropriate dosing, monitoring, and timing based on your individual health profile.

Rapamycin is an immunosuppressant even at low doses and requires provider oversight and appropriate monitoring. Side effects at therapeutic doses include impaired wound healing, mucositis, elevated lipids, and infection susceptibility. While these risks may be reduced at lower intermittent doses, they are not eliminated. Rapamycin also interacts with many medications metabolized through the CYP3A4 pathway. It is not appropriate for individuals who are immunocompromised, pregnant, or planning surgery in the near term.

This is a prescription drug used off-label. Dispensing requires a licensed provider to review your full health history, current medications, and laboratory baseline. It is not appropriate for self-directed use, and provider monitoring throughout the course of treatment is a requirement, not optional. The longevity evidence base for rapamycin in humans is compelling in preclinical terms but early in human clinical validation.